埃克替尼治疗晚期肺癌患者的疗效及对T细胞亚群水平的影响  

Efficacy of icotinib in the treatment of advanced lung cancer patients and its effect on the level of T cell subsets

作　　者：张倩 白黎峰 郑院青 李雪 ZHANG Qian;BAI Lifeng;ZHENG Yuanqing;LI Xue(Department of Pulmonary and Critical Care Medicine,General Hospital of Pingmei Shenma Medical Group,Pingdingshan 467000,He’nan,China)

机构地区：[1]平煤神马医疗集团总医院呼吸与危重症医学科,河南平顶山4670000

出　　处：《癌症进展》2024年第23期2638-2641,共4页Oncology Progress

摘　　要：目的探讨表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKI)靶向药物埃克替尼治疗晚期肺癌患者的疗效及对T细胞亚群水平的影响。方法将86例晚期肺癌患者按照治疗方案的不同分为对照组(n=45)和观察组(n=41)。对照组患者采取常规化疗,观察组患者采取常规化疗联合埃克替尼治疗。比较两组患者的临床疗效、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))水平、肺功能指标[用力肺活量(FVC)、最大呼气中期流量(MMEF)、第1秒用力呼气容积(FEV_(1))]及不良反应发生情况。结果观察组患者临床总控制率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患者CD3^(+)、CD4^(+)水平均高于治疗前和对照组,CD8^(+)水平低于治疗前和对照组,差异均有统计学意义(P<0.05)。治疗前后,两组患者FEV_(1)、FVC、MMEF比较,差异均无统计学意义(P>0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论EGFR-TKI靶向药物埃克替尼治疗晚期肺癌患者有较好的临床疗效,并能改善机体免疫功能,安全性良好。Objective To investigate the efficacy of epidermal growth factor receptor(EGFR)-tyrosine kinase inhibi-tor(TKI)targeting drug icotinib in the treatment of advanced lung cancer patients and its effect on the level of T cell sub-sets.Method A total of 86 patients with advanced lung cancer were divided into control group(n=45)and observation group(n=41)according to different treatment regimens.Control group received conventional chemotherapy,observation group received conventional chemotherapy combined with icotinib treatment.The clinical efficacy,T cell subsets(CD3^(+),CD4^(+),CD8^(+))levels,pulmonary function indicators[forced vital capacity(FVC),maximal mid-expiratory flow(MMEF),forced expiratory volume in one second(FEV_(1))]and the incidence of adverse reactions were compared between the two groups.Result The clinical total control rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in observation group were higher than those before treatment and control group,and the levels of CD8^(+)were lower than those before treatment and control group,the differences were statistically significant(P<0.05).Before and after treatment,there were no significant differ-ences in FEV_(1),FVC and MMEF between the two groups(P>0.05).There was no significant difference in the total inci-dence of adverse reactions between the two groups(P>0.05).Conclusion EGFR-TKI targeting drug icotinib has good clinical efficacy in the treatment of advanced lung cancer patients,and can improve the immune function of the body,with good safety.

关 键 词：晚期肺癌 表皮生长因子受体 酪氨酸激酶抑制剂 埃克替尼 免疫功能 肺功能 

分 类 号：R734.2[医药卫生—肿瘤]